Evaluation of Empiric β-Lactam Susceptibility Prediction among
| Autor: | Kyle, Spafford, Shawn, MacVane, Romney, Humphries |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Genotype
Enterobacteriaceae Infections Reproducibility of Results Bacteriology Microbial Sensitivity Tests biochemical phenomena metabolism and nutrition bacterial infections and mycoses beta-Lactam Resistance Anti-Bacterial Agents Carbapenem-Resistant Enterobacteriaceae Molecular Diagnostic Techniques Drug Resistance Multiple Bacterial polycyclic compounds Humans beta-Lactamase Inhibitors |
| Zdroj: | Journal of clinical microbiology. 57(10) |
| ISSN: | 1098-660X |
| Popis: | The use of rapid diagnostic tests (RDTs) for blood cultures has become standard of care in the United States to inform early antimicrobial optimization. The relative ability of genotypic and phenotypic approaches to identify beta-lactam susceptibility in Escherichia coli, Klebsiella spp., and Proteus mirabilis was evaluated, using incidence rates of resistance mechanisms to third-generation cephalosporins, aztreonam, and piperacillin-tazobactam seen across U.S. census regions. Overall, the presence of CTX-M, KPC, and/or NDM genes was 81% (range, 57 to 87%) sensitive for the prediction of ceftriaxone, ceftazidime, and aztreonam resistance and 73% (range, 25 to 90%) sensitive for the detection of piperacillin-tazobactam resistance. The sensitivity of KPC or NDM to predict imipenem or meropenem resistance was 94.3% overall, and for meropenem ranged from 70 to 100% across U.S. census regions. Institutions that use genotypic RDTs to inform therapeutic de-escalation decisions should be aware of the incidence-base performance across U.S. geographies and in different patient populations, where resistance rates may vary. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|